Chengwei Zhang
About Chengwei Zhang
Chengwei Zhang is the Director of Medicinal Chemistry at Cullgen Inc., a position he has held since 2021. He has extensive experience in medicinal chemistry, having previously worked in various research roles at institutions such as the Icahn School of Medicine at Mount Sinai and Baylor College of Medicine.
Current Role at Cullgen Inc.
Chengwei Zhang serves as the Director of Medicinal Chemistry at Cullgen Inc., a position he has held since 2021. In this role, he oversees the development of medicinal chemistry strategies and leads research initiatives aimed at discovering and optimizing new therapeutic compounds. His expertise contributes to the advancement of Cullgen's drug discovery programs.
Previous Experience at Cullgen Inc.
Prior to his current role, Chengwei Zhang worked at Cullgen Inc. as the Associate Director of Medicinal Chemistry from 2019 to 2021. During this time, he played a significant role in the medicinal chemistry team, focusing on compound design and optimization to support various drug discovery projects.
Postdoctoral Research Experience
Chengwei Zhang has extensive postdoctoral research experience. He was a Postdoctoral Researcher at the Icahn School of Medicine at Mount Sinai from 2017 to 2018. Before that, he completed postdoctoral positions at Baylor College of Medicine from 2014 to 2015 and at UT Southwestern Medical Center from 2015 to 2016. He also served as a Postdoctoral Research Fellow at Baylor College of Medicine from 2016 to 2017.
Educational Background
Chengwei Zhang obtained his Bachelor's degree in Applied Chemistry from Hubei University, where he studied from 2001 to 2005. He further pursued his education at the Shanghai Institute of Organic Chemistry, earning a Ph.D. in Organic Chemistry from 2007 to 2012. His academic background provides a strong foundation for his work in medicinal chemistry.
Experience in Pharmaceutical Industry
In addition to his academic roles, Chengwei Zhang has held positions in the pharmaceutical industry. He worked as an Associate Director at 药明康德 from 2018 to 2019, where he contributed to drug development efforts. His industry experience complements his research background and enhances his capabilities in medicinal chemistry.